Please assess the completion status of the following clinical trial:

Trial Title: Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria :~* Aged ≥ 6 months to \< 36 months.~* Considered to be in good health on the basis of reported medical history and limited physical examination.~* Available for the duration of the study (44 days +4 days).~* Parent/guardian is willing and able to provide informed consent.~* Parent/guardian is willing and able to meet protocol requirements.~Exclusion Criteria :~* Reported allergy to egg proteins, chicken proteins, or any other constituent of the vaccine.~* Previous history of influenza vaccination or documented history of influenza infection.~* An acute illness with or without fever (temperature \> 100.4 °F rectal) in the 72 hours preceding enrollment in the trial (defer enrollment).~* Clinically significant findings in vital signs or review of systems (investigator judgment; defer or exclude).~* Participation in any other clinical trial within 30 days prior to enrollment up to termination of the subject's participation in the study.~* Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth.~* Personal or immediate family history of congenital immune deficiency.~* Developmental delay, neurologic disorder, or seizure disorder.~* Chronic medical, congenital, or developmental disorder.~* Known human immunodeficiency virus (HIV)-positive mother.~* Prior history of Guillain-Barré syndrome.~* Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 36 Months
- Healthy Volunteers: t

Study Arms:
- Study Group (Type: EXPERIMENTAL): Participants received 2 doses of Fluzone® vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).